Condition: Dementia & Alzheimer's

What It Is

Dementia is a lasting decline in memory, thinking or judgment that is severe enough to interfere with everyday life. It is not one disease but several, each with a different cause and course, and telling them apart changes what helps.

Alzheimer's disease is the most common. Amyloid plaques and tau tangles build in the brain over years, usually starting with short-term memory and word-finding. The changes begin in midlife, long before any symptom, so what you do in your forties and fifties affects the risk decades later.

Vascular dementia comes from strokes, small-vessel disease and poor blood flow, and it often progresses in steps, with slowed thinking and trouble planning as much as memory loss. It shares its risk factors with heart disease, which makes it the most preventable of the group.

Lewy body dementia brings fluctuating attention, visual hallucinations, movement changes like Parkinson's, and vivid acting-out of dreams. It matters to recognize early, because certain antipsychotic drugs can cause severe reactions in these patients.

Mixed dementia is more than one process at once, most often Alzheimer's changes together with vascular damage. In people over 80 this combination is more common than any single pure type, which is part of why vascular risk factors matter even for Alzheimer's.

Mild cognitive impairment sits one step earlier: measurable memory or thinking changes that are greater than normal aging, with daily life still largely intact. It is a stage, and it does not always progress. Some people go on to dementia, some stay stable for years, and a meaningful number return to normal, especially when a reversible cause such as a medication, thyroid trouble, low vitamin B12, poor sleep or low mood is found and treated. It is the point at which attention pays off most.

Whatever the type, dementia reflects the health of the whole body, not the brain alone. The same process that stiffens and narrows arteries drives vascular damage in the brain, so what protects the heart is, on current evidence, among the better-supported things for the mind. One pattern stands apart from the slow decline of dementia: confusion that comes on over hours or a few days.

Confusion that comes on over hours or a few days is usually delirium or another treatable problem, and it needs same-day attention. The signs are in the red flags at the end.

Prevention: The Risk You Can Change

The strongest lever in dementia is the risk you can change, and there is more of it than most people are told.

The Lancet Commission's 2024 report estimates that about 45% of dementia cases are tied to fourteen modifiable risk factors acted on across a lifetime. The larger contributors it models fall across three stages of life:

• Early life: less education.
• Midlife: hearing loss, high LDL cholesterol, high blood pressure, obesity, heavy drinking and head injury.
• Later life: smoking, depression, physical inactivity, diabetes, air pollution, social isolation and untreated vision loss.

Untreated vision loss and high cholesterol were added since the 2020 report. That 45% is a population estimate, not a promise to any one person. It assumes the links are causal and that each factor could be fully removed, the factors overlap, and it describes the ceiling on what is theoretically avoidable, which is more than any one person can expect to remove.

Even read cautiously it points the same way, because the same levers protect the heart and blood vessels as well as the brain.

This is risk reduction, not a cure or a guarantee. No diet, supplement or single habit has been shown to prevent Alzheimer's outright, so what the research supports is lowering the odds and, for some, delaying onset. That is a smaller claim than the headlines make and still worth a great deal, because dementia risk compounds over decades and the earliest changes begin in midlife.

Much of the evidence for the individual levers is observational, which shows a pattern but cannot prove cause. The people who exercise, eat well and stay connected also tend to be wealthier, better educated and healthier in ways that independently lower dementia risk, and early brain changes can alter how people live years before a diagnosis. Where trials exist, they are named below, and the graded record follows.

Blood pressure has the best trial support. In the SPRINT MIND trial, driving systolic pressure toward 120 rather than 140 lowered the risk of mild cognitive impairment by about 19% and the combined outcome of impairment or dementia by about 15%. Dementia alone fell in the same direction but did not reach statistical significance, partly because the trial was stopped early once the heart benefit was clear, so it was left underpowered for dementia specifically. The direction and the vascular logic are consistent, and controlling blood pressure protects the heart regardless.

Hearing loss is the single largest factor on the Lancet list, and correcting it is low-risk. Across the whole ACHIEVE trial, hearing aids did not slow three-year cognitive decline more than health education. In a prespecified group at higher risk, older adults with more risk factors, the same intervention slowed decline by about 48%. The overall result was null and the 48% comes from one subgroup, so it needs confirmation, but hearing aids help communication and mood in any case.

Movement, diet and sleep each point the right way, with mixed trial support.

Long cohort studies link regular activity to lower dementia risk. A two-year structured exercise program in previously sedentary older adults, the LIFE trial, did not improve thinking more than health classes. Exercise still protects the heart, mood and the vascular pathway the brain depends on, which is reason enough to do it. It has not been shown to reverse decline once that decline has begun late in life.

A Mediterranean or MIND eating pattern was linked in a large cohort to about 53% less Alzheimer's in the closest followers, but a three-year randomized trial of the MIND diet found no cognitive benefit over the control diet. The pattern is heart-safe, and its cognitive benefit is better supported by observation than by trial.

Sleeping six hours or less in midlife tracked about 30% more dementia over 25 years in the Whitehall II study. The diseases that cause dementia disturb sleep years before diagnosis, so some of that link likely runs the other way.

The clearest single signal that several levers together help comes from the Finnish FINGER trial, which combined diet counseling, exercise, cognitive training and vascular monitoring for two years and produced modestly better overall cognitive scores than general advice. Larger and longer trials to confirm a lasting effect on dementia itself are still running.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Cognition

Cholinesterase inhibitors improve Alzheimer's cognition about 2.4 ADAS-Cog pointsStrong

In plain terms

The standard Alzheimer's pills give a modest improvement in memory and daily function for a time.

In detail

Across randomized trials, the cholinesterase inhibitors donepezil, galantamine and rivastigmine improved cognition in mild-to-moderate Alzheimer's disease by about 2.4 points (-2.37, 95% CI -2.73 to -2.02) on the 70-point ADAS-Cog scale over six months, with smaller benefits in daily function and behavior. The three drugs performed similarly. Measured in: Adults with mild-to-moderate Alzheimer's disease across pooled randomized, placebo-controlled trials. The benefit is symptomatic and does not slow the underlying disease, and side effects such as nausea, diarrhea, slow heart rate and appetite loss are common enough that some people stop the drug.

The study · 1

Birks, Cholinesterase inhibitors for Alzheimer's disease (Cochrane review) · Cochrane Database Syst Rev 2006;(1):CD005593

Lecanemab slowed decline about 27% over 18 months, with brain swelling in 12.6%Strong

In plain terms

Lecanemab slowed decline by about a quarter over 18 months in early Alzheimer's, with brain swelling in about one in eight people.

In detail

In 1795 people with early Alzheimer's disease, lecanemab slowed decline on the CDR-SB scale by 27% over 18 months, an adjusted difference of 0.45 points (1.21 versus 1.66), while clearing amyloid from the brain. Brain swelling (ARIA-E) occurred in 12.6% versus 1.7% on placebo, microbleeds and surface bleeding (ARIA-H) in 17.3%, and infusion reactions in about 26%. Measured in: 1795 adults aged 50 to 90 with early Alzheimer's disease and confirmed amyloid in the Clarity AD trial. The absolute difference is small and its everyday meaning is debated. The drug requires confirmed amyloid, twice-monthly infusions and repeated MRI monitoring, and the brain swelling and bleeding can be serious, more so in carriers of two copies of the APOE4 gene.

The study · 1

van Dyck et al., Lecanemab in early Alzheimer's disease (Clarity AD) · N Engl J Med 2023;388(1):9-21

Donanemab slowed decline about 22% to 35% over 18 months, with brain swelling in about 24%Strong

In plain terms

Donanemab slowed decline by roughly a fifth to a third over 18 months, with brain swelling in about a quarter of people.

In detail

In 1736 people with early symptomatic Alzheimer's disease, donanemab slowed decline over 18 months, by about 35% on a combined disease scale in those with low-to-medium tau and about 22% across the whole group, while clearing amyloid. Brain swelling (ARIA-E) occurred in about 24%, serious cases in a small minority, and three deaths were linked to the drug. Measured in: 1736 adults aged 60 to 85 with early symptomatic Alzheimer's disease and confirmed amyloid and tau in TRAILBLAZER-ALZ 2. As with lecanemab the absolute benefit is modest and contested, and the risk of brain swelling and bleeding, including rare deaths, means it is used only in early confirmed disease with MRI monitoring.

The study · 1

Sims et al., Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial · JAMA 2023;330(6):512-527

Years of ginkgo did not lower the risk of developing dementiaStrong · no effect

In plain terms

Taking ginkgo for years did not lower the chance of developing dementia in a large trial of older adults.

In detail

In the GEM trial, 3069 adults aged 75 and over took ginkgo biloba 120 mg twice daily or placebo for a median of about six years. Ginkgo did not reduce the incidence of all-cause dementia or Alzheimer's disease (hazard ratio 1.12 for dementia, 95% CI 0.94 to 1.33). Measured in: 3069 community-dwelling adults aged 75 and over, with normal cognition or mild cognitive impairment at entry. This tested prevention in people already aged 75 and over and does not address use earlier in life, but it is the largest prevention trial of ginkgo and the result was clearly null.

The study · 1

DeKosky et al., Ginkgo biloba for prevention of dementia: a randomized controlled trial (GEM Study) · JAMA 2008;300(19):2253-2262

About 45% of dementia risk is tied to fourteen factors you can act onModerate

In plain terms

A 2024 expert commission estimated that about 45% of dementia cases are linked to fourteen risk factors people can act on, such as hearing loss, high blood pressure and inactivity.

In detail

The 2024 Lancet Commission attributes around 45% of dementia cases to fourteen modifiable risk factors acted on across life. The larger contributors it models are less education in early life, hearing loss and high LDL cholesterol in midlife, and social isolation in later life, with hypertension, obesity, smoking, depression, physical inactivity, diabetes, excessive alcohol, traumatic brain injury, air pollution and untreated vision loss making up the rest. Untreated vision loss and high LDL cholesterol were added since the 2020 report. Measured in: A commission synthesis of cohort and trial evidence estimating population-attributable fractions for dementia worldwide. This is a population-attributable estimate that assumes the associations are causal and that each factor could be fully removed, and the factors overlap, so it is a ceiling on what is theoretically avoidable rather than a promise to any one person.

The study · 1

Livingston et al., Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission · Lancet 2024;404(10452):572-628

Intensive blood-pressure control cut mild cognitive impairment about 19%Moderate

In plain terms

Lowering blood pressure more aggressively cut the risk of mild cognitive impairment by about 19%, roughly a fifth; the drop in dementia itself was in the same direction but not statistically certain.

In detail

Randomizing adults aged 50 and over with hypertension to a systolic target below 120 rather than below 140 reduced mild cognitive impairment (hazard ratio 0.81, 95% CI 0.69 to 0.95) and the combined outcome of mild cognitive impairment or probable dementia (0.85, 0.74 to 0.97). Probable dementia alone was lower in the same direction but did not reach significance (0.83, 0.67 to 1.04). Measured in: 9361 adults aged 50 and over with hypertension and raised cardiovascular risk in the SPRINT MIND trial. The trial was stopped early once the cardiovascular benefit was clear, which left it underpowered for dementia specifically, and the intensive target requires more medicines and closer monitoring.

The study · 1

Williamson et al., Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial (SPRINT MIND) · JAMA 2019;321(6):553-561

Hearing aids did not slow decline overall, but slowed it about 48% in the highest-risk groupModerate · no effect

In plain terms

Hearing aids did not slow thinking decline overall, but in the group at highest risk they slowed it by roughly half.

In detail

Over three years, hearing aids with audiologic support did not slow global cognitive decline more than a health-education control across the whole ACHIEVE trial (between-group difference close to zero). In a prespecified group at higher risk, older adults recruited from an existing cardiovascular cohort with more risk factors, the same intervention slowed cognitive decline by about 48%. Measured in: 977 adults aged 70 to 84 with untreated mild-to-moderate hearing loss in the ACHIEVE randomized trial. The overall result was null, and the 48% figure comes from one prespecified subgroup rather than the whole trial, so it needs confirmation. Correcting hearing carries clear benefits for communication and mood in any case.

The study · 1

Lin et al., Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE) · Lancet 2023;402(10404):786-797

A two-year diet, exercise and brain-training program modestly improved cognition (FINGER)Moderate

In plain terms

Working on diet, exercise, brain training and heart-health together for two years led to modestly better thinking scores than general advice.

In detail

A two-year program combining dietary counseling, exercise, cognitive training and vascular risk monitoring produced better overall cognitive test scores than general health advice, a between-group difference of about 0.02 per year on a standardized composite favoring the program, with clearer gains in executive function and processing speed. Measured in: 1260 adults aged 60 to 77 at raised risk of dementia in the Finnish FINGER trial. The gains were modest and measured on cognitive tests rather than on dementia diagnoses, and larger, longer trials to confirm a lasting effect on dementia itself are still running.

The study · 1

Ngandu et al., A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) · Lancet 2015;385(9984):2255-2263

A two-year exercise program did not improve overall thinking in sedentary eldersModerate · no effect

In plain terms

A two-year exercise program did not improve overall thinking more than health classes in previously inactive older adults.

In detail

A 24-month structured physical-activity program did not improve global cognition compared with a health-education control in sedentary older adults. There was a hint of better executive function among those aged 80 and over and those with lower baseline function, but the primary cognitive endpoint showed no overall difference. Measured in: 1635 sedentary adults aged 70 to 89 in the LIFE randomized trial. This tested exercise begun late in life for a cognitive endpoint and does not speak to a lifetime of activity; the participants were already at risk of mobility problems. Activity still benefits the heart, mood and the vascular pathway that reaches dementia.

The study · 1

Sink et al., Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial · JAMA 2015;314(8):781-790

A three-year MIND-diet trial found no cognitive benefit over the controlModerate · no effect

In plain terms

In a three-year trial, following the MIND diet did not improve thinking more than the comparison diet.

In detail

Randomizing 604 older adults with a family history of dementia to the MIND diet or a control diet, both with mild calorie restriction, produced no significant difference in cognitive change or brain MRI measures over three years. Both groups improved slightly on the cognitive composite. Measured in: 604 adults aged 65 and over, overweight with a suboptimal diet and a family history of dementia. Both groups cut calories and lost weight, which may have narrowed any difference, and three years may be too short to reveal an effect on a disease that develops over decades.

The study · 1

Barnes et al., Trial of the MIND diet for prevention of cognitive decline in older persons · N Engl J Med 2023;389(7):602-611

Top MIND-diet adherence tracked 53% less Alzheimer's in a cohortEmerging

In plain terms

People who most closely followed the MIND diet developed Alzheimer's about half as often as those who followed it least.

In detail

In a prospective cohort of 923 older adults followed about 4.5 years, those in the top third for MIND-diet adherence had a 53% lower rate of Alzheimer's disease than the bottom third (hazard ratio 0.47, 95% CI 0.26 to 0.76), and even middle-third adherence carried a 35% lower rate. Measured in: 923 adults aged 58 to 98 in the Rush Memory and Aging Project. What could explain it instead: People who eat this way tend to be more educated, more physically active and higher income, and to have less vascular disease, all independently linked to lower dementia risk; early cognitive change can also alter how people eat, running the association the other way.. This is observational and cannot show cause; the effect estimate comes from self-reported eating patterns over a single window.

The study · 1

Morris et al., MIND diet associated with reduced incidence of Alzheimer's disease · Alzheimers Dement 2015;11(9):1007-1014

Sleep

Six hours or less of sleep in midlife tracked about 30% more dementiaEmerging · risk

In plain terms

People who regularly slept six hours or less in midlife were about 30% more likely to develop dementia than seven-hour sleepers.

In detail

In the Whitehall II cohort of 7959 adults followed up to 25 years, a persistent short sleep of six hours or less at ages 50 to 70 was associated with about 30% higher dementia risk than a seven-hour sleep (hazard ratio 1.30, 95% CI 1.00 to 1.69). Short sleep measured at age 50 and at age 60 showed the same direction. Measured in: 7959 British civil servants in the Whitehall II study, followed a median of about 25 years with 521 dementia cases. What could explain it instead: The diseases that cause dementia disrupt sleep years before diagnosis, so short sleep in midlife may be an early sign of the process rather than a cause of it; depression and other conditions affect both sleep and dementia risk as well.. This is observational, so it shows association rather than cause, and the confidence interval reaches the edge of no effect.

The study · 1

Sabia et al., Association of sleep duration in middle and old age with incidence of dementia · Nat Commun 2021;12(1):2289

What To Do First

None of this needs a prescription to begin, most of it is free or cheap, and the same habits protect the heart. Midlife is when they count for most, but starting later still helps. Pick a few you can hold steadily rather than trying to do all of them at once.

1

Get your hearing checked, and use aids if you need themFree to $$Easy

Hearing loss is the largest single factor on the Lancet list, and correcting it is low-risk whatever it does for memory. A hearing test is often free, and over-the-counter aids have made this far cheaper than it used to be.

2

Know your blood pressure and treat it from midlifeFree to $Easy

Blood pressure has the best trial support of any dementia lever, and it protects the heart at the same time. A home monitor costs little; if the average runs high, that is the case to take to a clinician, and it is your strongest single move.

3

Move most days, aerobic and some strengthFreeModerate

Regular activity is linked to lower risk and helps mood, sleep and the blood vessels the brain depends on. Walking is free and counts; adding some resistance work protects the muscle and the metabolism that go with a healthy brain.

4

Eat a Mediterranean or MIND-style plateFree to $Moderate

Build meals on vegetables, beans, whole grains, olive oil, fish and berries, and cut ultra-processed food and sugary drinks. Canned fish, frozen vegetables and dried beans make this cheap, and the pattern is good for the heart whether or not it moves the cognitive numbers.

5

Protect your sleep, and get snoring or apnea checkedFreeModerate

Aim for a steady seven hours or so. Loud snoring, gasping or witnessed pauses in breathing are worth getting looked at, since treating sleep apnea helps blood pressure, mood and daytime thinking.

6

Stay connected and keep learningFreeEasy

Social contact, purpose and demanding new learning are all linked to lower risk. A standing meet-up, a language, an instrument or a craft asks more of the brain than a puzzle app, and it costs nothing but time.

7

Rule out the reversible causes if thinking changesFree to $Easy

Before accepting a dementia label, low vitamin B12, thyroid trouble, depression, sleep apnea, alcohol and certain medications are all worth checking, because any of them can mimic or worsen the picture. B12 and thyroid can be ordered through direct-to-consumer testing as well as through a clinician.

Where the Medicines Fit

The groundwork above is the foundation, and the medicines come on top of it. No drug yet halts the underlying disease or turns it back, and it helps to be clear about what each one does.

Cholinesterase inhibitors, the drugs donepezil, galantamine and rivastigmine, give a modest improvement in memory and daily function for a time. Across randomized trials they lifted cognition by about 2.4 points on the 70-point ADAS-Cog scale over six months, with smaller gains in daily function and behavior, and the three perform similarly. They ease symptoms; they do not slow the underlying disease, and the benefit lasts only while the drug is taken.

Nausea, diarrhea, a slow heart rate and appetite loss are common enough that some people stop. For moderate-to-severe disease, memantine is sometimes added, again for a modest symptomatic effect. In Lewy body dementia the cholinesterase inhibitors can help attention and hallucinations specifically.

The anti-amyloid antibodies are the newest and the most debated. Both clear amyloid from the brain and both slow early Alzheimer's by a modest amount. Lecanemab slowed decline on the CDR-SB scale by 27% over 18 months in early disease, a difference of 0.45 points on an 18-point scale (1.21 against 1.66 on placebo). Donanemab slowed decline by about 35% in people with lower tau and about 22% across the whole group on a combined disease scale over the same period.

The safety concern is serious. Brain swelling, called ARIA, occurred in 12.6% of people on lecanemab and about 24% on donanemab. Small bleeds are common alongside it. Most cases are silent on a scan, though some are serious, and donanemab's trial recorded three deaths linked to the drug. The risk is higher in people carrying two copies of the APOE4 gene.

For all these reasons the antibodies are used only in early, confirmed Alzheimer's, with genetic testing and repeated MRI scans, and the decision is made with a specialist who weighs a fraction of a point of slowing against the swelling and bleeding risk. Whether the benefit is large enough to be worth it in daily life is contested.

Much of living well with dementia is not about drugs at all. Treating pain, constipation, poor sleep and infection often settles agitation better than any sedative. Routine, orientation, music and familiar company help, and antipsychotics are reserved for serious distress because they raise the risk of stroke and death and can be dangerous in Lewy body disease. Caring for someone with dementia is demanding, and the strain on the person providing care affects two lives at once. Support, respite and a plan made early rather than in a crisis are part of the treatment, not an extra.

What Does Not Help, and What to Rule Out First

A large industry sells prevention that the evidence does not support. Ginkgo biloba is the clearest example: in a trial of more than three thousand adults aged 75 and over taking it for about six years, it did not lower the rate of dementia or Alzheimer's at all. Coconut oil, most nootropics and the supplements marketed for brain health have no trial evidence for preventing Alzheimer's or slowing its course, and a few carry their own risks, including bleeding with ginkgo alongside blood thinners.

Brain-training apps make you better at the game and at very similar tasks, with little carryover to everyday thinking, so demanding, varied learning is a better use of the same effort. The levers in the prevention section lower the odds; the products sold as prevention mostly do not.

Before any of this applies, one step comes first when thinking changes: rule out the causes that are reversible. Low vitamin B12, an underactive thyroid, depression, sleep apnea, heavy alcohol use and certain medications can all mimic or worsen dementia, and normal-pressure hydrocephalus, a treatable build-up of fluid around the brain that brings a triad of unsteady walking, incontinence and cognitive slowing, can improve with treatment.

A first, thorough workup for these is the reason a slow cognitive change is a doctor's visit rather than a diagnosis you accept on your own. It is also why mild cognitive impairment is not treated as certain progression, since a share of people stay stable or return to normal once a reversible cause is found and fixed.

Go Deeper

• High blood pressure: how to measure it right and what lowers it, the best-supported dementia lever and a heart protector in its own right.
• Hearing protection: guarding the hearing whose loss is the single largest modifiable risk factor.
• Neuroplasticity: how the adult brain rewires with effort, exercise and sleep, including the year of walking that regrew the memory hippocampus about 2%.
• Mediterranean diet: the eating pattern behind the diet findings here, plate by plate.
• Type 2 diabetes: the metabolic and vascular pathway that reaches the brain, and how to change it.
• Insulin and glucose: the biology linking blood sugar, blood vessels and cognition.

The Chinese Medicine View

The Chinese Medicine View

Chinese medicine has no category that maps onto Alzheimer's or a scan showing amyloid; it reads the person. The classical frame for failing memory and cognition is Dai (呆), dullness, tied above all to the Kidney, which is said to rule the bones and generate marrow, and the brain is named the Sea of Marrow. When the Kidney essence that fills that sea declines with age, the tradition expects memory, hearing and the bones to weaken together, which is a description of a pattern and not an account of the disease. The Heart is held to house the Shen, the spirit and mental clarity, so classical thinking looks at the Heart and Kidney as much as the head itself. Read these as an interpretive lens on how a person presents, not as a treatment for dementia, for which Chinese medicine has no demonstrated cure. There are places the tradition would work differently rather than reach for tonics: a thick, greasy tongue coat and a heavy, muddled presentation are read as Phlegm misting the orifices, which calls for transforming Phlegm rather than adding rich, cloying essence-tonics that can make it worse, and sudden confusion is treated as a separate, urgent picture entirely.

Kidney essence depletion, empty Sea of Marrow

Slow forgetfulness with age alongside low back and knee weakness, hearing decline, night-time urination and a fatigue that rest does not fully mend, with a pale or thin tongue. The direction is to tonify the Kidney and nourish essence and marrow, distinguishing a colder Yang-deficient picture from a drier Yin-deficient one.

Phlegm misting the orifices

A muddled, foggy quality, heaviness, a thick greasy tongue coat, sometimes emotional dullness or apathy more than pure memory loss. The direction is to transform Phlegm and open the orifices rather than to tonify, since tonics can thicken the obstruction.

Heart and Spleen deficiency

Poor memory with palpitations, anxiety, poor sleep, low appetite and tiredness, with a pale complexion. Chinese medicine sees the Heart housing the spirit and the Spleen building the blood that nourishes it, and the direction is to strengthen both so the mind is settled and fed.

Cautions and Interactions

Extra restraint

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Anticholinergic medicines dull thinking

A long list of common drugs, some for bladder control, allergies, sleep and older depression, have an anticholinergic effect that clouds thinking, and heavy use over years is linked to higher dementia risk. If thinking is a concern, ask a prescriber or pharmacist to review the whole list, since many have gentler alternatives.

Antipsychotics can be dangerous in Lewy body dementia

People with Lewy body dementia can have severe, sometimes life-threatening reactions to certain antipsychotic drugs, so a diagnosis matters before any is used for hallucinations or agitation. In dementia generally, antipsychotics raise the risk of stroke and death, so they are reserved for serious distress, and treating pain, sleep, constipation and infection comes first.

Anti-amyloid antibodies need genotyping and MRI monitoring

Lecanemab and donanemab cause brain swelling or small bleeds (ARIA) in a meaningful minority, more often and more seriously in people carrying two copies of the APOE4 gene, which is why testing for it and repeated MRI scans are part of the decision. Blood thinners add to the bleeding risk. New headache, confusion, vision change or weakness during treatment is a reason to contact the treating team the same day.

Ginkgo and blood thinners

Ginkgo has a mild blood-thinning effect and can add to the risk of bleeding alongside anticoagulants, antiplatelet drugs or before surgery, even though the large prevention trial found it did not lower dementia risk.

Most of lowering your risk is yours to do and low-harm, and midlife is when it counts for most. Where a medicine or a monitored treatment is involved, that decision is shared with a clinician, and if thinking changes, ruling out the reversible causes comes first.

When to See Someone

Most of lowering dementia risk is steady, long-term work on blood pressure, hearing, movement and sleep, done well before anything urgent. A few situations are different and need a doctor rather than a plan on a page. These are the signs to get seen about:

• Confusion that comes on suddenly, over hours or a few days, or a sharp change in alertness, which can be delirium from infection, medication, dehydration or a metabolic problem and needs same-day assessment(seek urgent care)
• A step-change decline in thinking over weeks, or new weakness, numbness, trouble speaking or a facial droop, which can mean a stroke or another treatable cause and needs prompt care(seek urgent care)
• A first, thorough workup for reversible contributors before accepting a dementia label, including thyroid, vitamin B12, medications, depression, sleep apnea, alcohol and normal-pressure hydrocephalus, any of which can mimic or worsen the picture
• New headache with confusion, unsteadiness or falls in someone on blood thinners or after a head injury, which can point to bleeding around the brain(seek urgent care)
• New or worsening headache, confusion, vision changes or weakness in someone receiving an anti-amyloid antibody, which can be a sign of the brain swelling or microbleeds these drugs can cause and needs urgent contact with the treating team(seek urgent care)
• Safety concerns that are already here: getting lost while driving, leaving the stove on, wandering, or trouble managing medications, all of which are worth raising early rather than after a crisis
• Hallucinations, marked day-to-day fluctuation in alertness, or acting out dreams, which point toward Lewy body dementia and change which drugs are safe, so a diagnosis matters before any antipsychotic is used
• Strain, low mood or exhaustion in the person providing care, which is common, which affects two lives at once, and for which support is available

None of this is meant to frighten you. A large part of dementia risk tracks with things you can act on, most of them the same habits that protect the heart, and midlife is when they count for most. The medicines that exist are decided with a specialist, and the first move at any worrying change is to rule out the causes that are treatable, which is exactly where a doctor comes in.

Common Questions

How much of dementia can actually be prevented?

Not all of it, and more than most people think. The Lancet Commission's 2024 report ties about 45% of dementia cases to fourteen modifiable risk factors acted on across a lifetime, such as hearing loss, high blood pressure, inactivity, diabetes and smoking. That figure is a population estimate rather than a promise to any one person, and it assumes the links are causal and could be fully removed. What it means in practice is that a meaningful share of the risk is in your hands, that the earlier you act the better, and that the same changes protect the heart, so this is risk reduction rather than a guarantee.

What is the single most effective thing I can do?

For most people the gain comes from several changes together. If one must be singled out, blood pressure has the best trial evidence, and hearing is the largest single factor on the Lancet list. In the SPRINT MIND trial, driving systolic pressure toward 120 rather than 140 cut mild cognitive impairment by about 19%. Correcting hearing loss is low-risk whatever it does for memory. Both sit alongside regular movement, a Mediterranean or MIND-style plate, decent sleep and staying connected, which all point the same way.

Do the new Alzheimer's drugs work?

The effect is modest. Lecanemab slowed decline by about 27% over 18 months in early Alzheimer's, a difference of 0.45 points on an 18-point scale, and donanemab slowed it by roughly a fifth to a third. Both clear amyloid, and both cause brain swelling, called ARIA, in a meaningful minority: about 12.6% on lecanemab and 24% on donanemab, with rare deaths. They are used only in early, confirmed disease with genetic testing and MRI monitoring, decided with a specialist. Whether the slowing is large enough to be worth the risk in daily life is contested.

Do cholinesterase inhibitors change the disease?

No, they ease the symptoms for a time. Donepezil, galantamine and rivastigmine improved cognition by about 2.4 points on a 70-point scale over six months in trials, with smaller gains in daily function, and the benefit lasts only while the drug is taken. They do not slow the underlying disease, and side effects such as nausea, a slow heart rate and appetite loss lead some people to stop.

Does the MIND or Mediterranean diet prevent dementia?

It helps the heart for certain, and the brain benefit is better supported by observation than by trial. In a large cohort, the closest followers of the MIND diet developed Alzheimer's about half as often as the least, but a three-year randomized trial found the MIND diet did not improve thinking more than a comparison diet. People who eat this way also tend to differ in education, income and activity, which lower dementia risk on their own. The plate is safe and good for you, so adopt it for its heart and general-health benefits while treating the cognitive effect as promising rather than proven.

My memory is getting worse. Does that mean dementia?

Not necessarily, and the first step is to rule out the causes that are reversible. Low vitamin B12, an underactive thyroid, depression, poor sleep, heavy alcohol use, certain medications and normal-pressure hydrocephalus can all mimic or worsen memory trouble, and treating them can turn it around. Mild cognitive impairment, the stage before dementia, does not always progress: some people stay stable for years and some return to normal, particularly once a reversible cause is found. A thorough workup is the reason a slow cognitive change is a doctor's visit rather than a conclusion to reach on your own.